Comparative Pharmacology
Head-to-head clinical analysis: LETERMOVIR versus REBETOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LETERMOVIR versus REBETOL.
LETERMOVIR vs REBETOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Letermovir is an antiviral agent that inhibits the human cytomegalovirus (CMV) terminase complex, specifically the pUL56 subunit, thereby preventing viral DNA processing and packaging.
Ribavirin, a guanosine analog, inhibits viral RNA-dependent RNA polymerase and inosine monophosphate dehydrogenase, leading to a decrease in intracellular guanosine triphosphate pools and impairment of viral RNA synthesis.
480 mg orally once daily (two 240 mg tablets).
Oral: 400-600 mg twice daily (800-1200 mg/day) based on body weight (≤75 kg: 400 mg twice daily; >75 kg: 600 mg twice daily) in combination with interferon alfa or peginterferon alfa.
None Documented
None Documented
Clinical Note
moderateLetermovir + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Letermovir."
Clinical Note
moderateLetermovir + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Letermovir."
Clinical Note
moderateLetermovir + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Letermovir."
Clinical Note
moderateLetermovir + Dronedarone
The terminal elimination half-life is approximately 12 hours (range 10–18 hours) in healthy subjects, allowing once-daily dosing.
Terminal elimination half-life: 120-200 hours (multiple doses, due to extensive accumulation in erythrocytes). Single dose: 24-36 hours. Clinically, steady state is reached in approximately 4 weeks.
Letermovir is primarily eliminated via biliary/fecal excretion (approximately 93% of the dose recovered in feces, with <2% as unchanged drug) and renal excretion accounts for <7% (mostly as metabolites, <1% unchanged).
Renal: 10-15% unchanged; biliary/fecal: 60-70% as metabolites; pulmonary excretion of CO2 contributes to elimination of ribavirin's triazole moiety. Approximately 10-20% excreted in feces as unchanged drug and metabolites.
Category C
Category C
Antiviral
Antiviral
"The metabolism of Dronedarone can be decreased when combined with Letermovir."